Brokerages Set BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) PT at $15.17

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) has been assigned an average rating of “Moderate Buy” from the six analysts that are covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $15.17.

A number of equities research analysts have weighed in on the company. Evercore ISI lifted their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. Finally, Needham & Company LLC boosted their price target on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research note on Monday, January 13th.

BioCryst Pharmaceuticals Stock Performance

Shares of BioCryst Pharmaceuticals stock opened at $7.64 on Thursday. BioCryst Pharmaceuticals has a one year low of $4.03 and a one year high of $8.88. The stock has a market cap of $1.58 billion, a price-to-earnings ratio of -12.52 and a beta of 1.76. The stock has a 50 day moving average price of $7.57 and a 200-day moving average price of $7.66.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Monday, November 4th. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.07). The business had revenue of $117.10 million for the quarter, compared to the consensus estimate of $113.99 million. BioCryst Pharmaceuticals’s revenue was up 35.1% on a year-over-year basis. During the same period in the prior year, the business posted ($0.19) earnings per share. Sell-side analysts predict that BioCryst Pharmaceuticals will post -0.38 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Counterweight Ventures LLC increased its stake in BioCryst Pharmaceuticals by 591.7% during the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company’s stock worth $710,000 after buying an additional 79,884 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of BioCryst Pharmaceuticals by 40.7% in the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company’s stock valued at $2,274,000 after purchasing an additional 86,571 shares during the period. Principal Financial Group Inc. increased its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock worth $3,127,000 after buying an additional 375,890 shares during the last quarter. Rice Hall James & Associates LLC raised its position in BioCryst Pharmaceuticals by 4.0% in the third quarter. Rice Hall James & Associates LLC now owns 2,163,743 shares of the biotechnology company’s stock valued at $16,444,000 after purchasing an additional 84,102 shares during the period. Finally, Fisher Asset Management LLC lifted its position in BioCryst Pharmaceuticals by 16.9% in the third quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after buying an additional 481,359 shares during the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.